Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × perifosine × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioma 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Solid Tumors 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 105 Dexamethasone 59 fludarabine phosphate 48 Cytarabine 48 Rituximab 46 fludarabine 45 Lenalidomide 35 Gemcitabine 35 Peripheral Blood Stem Cell Transplantation 34 Etoposide 34 Radiotherapy 32 pembrolizumab 30 Filgrastim 30 Busulfan 30 Carboplatin 28 Methotrexate 27 Cyclosporine 27 Melphalan 26 Cisplatin 26 Mycophenolic Acid 25 venetoclax 24 Paclitaxel 23 Bortezomib 23 Whole-Body Irradiation 21 Antilymphocyte Serum 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Temozolomide 19 Oxaliplatin 18 Bendamustine Hydrochloride 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01049841 2017-03-10

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡